Volume 15, Number 8—August 2009
Spread of Cryptococcus gattii into Pacific Northwest Region of the United States
On This Page
Cryptococcus gattii has emerged as a human and animal pathogen in the Pacific Northwest. First recognized on Vancouver Island, British Columbia, Canada, it now involves mainland British Columbia, and Washington and Oregon in the United States. In Canada, the incidence of disease has been one of the highest worldwide. In the United States, lack of cryptococcal species identification and case surveillance limit our knowledge of C. gattii epidemiology. Infections in the Pacific Northwest are caused by multiple genotypes, but the major strain is genetically novel and may have emerged recently in association with unique mating or environmental changes. C. gattii disease affects immunocompromised and immunocompetent persons, causing substantial illness and death. Successful management requires an aggressive medical and surgical approach and consideration of potentially variable antifungal drug susceptibilities. We summarize the study results of a group of investigators and review current knowledge with the goal of increasing awareness and highlighting areas where further knowledge is required.
Cryptococcus gattii (formerly C. neoformans var. gattii) (1) is a basidiomycotic yeast acquired by inhalation. In a susceptible host, the disease (cryptococcosis), caused by C. gattii and the congeneric pathogen C. neoformans, usually results in pneumonia or dissemination to distant tissues, especially to the central nervous system. Some studies have shown that C. gattii appears to differ from other cryptococcal pathogens in phenotypic characteristics, natural habitat, epidemiology, clinical disease manifestations and response to antifungal drugs. We briefly summarize these features before discussing the emergence of C. gattii in the Pacific Northwest region of Canada and the United States.
Based on the distribution of specific antigenic determinants on the polysaccharide capsule, pathogenic cryptococci have been divided into capsular serotypes B and C (both C. gattii), A (C. neoformans var. grubii), D (C. neoformans var. neoformans), and the hybrid diploid AD (1). Clinical and environmental C. gattii isolates obtained from most parts of the world belong to serotype B (2), the serotype also responsible for cryptococcal disease in the Pacific Northwest. The global distribution of C. gattii serotype C appears relatively more geographically restricted (2–4).
C. gattii causes disease in healthy, immunocompetent persons and in persons with immunosuppressive conditions, including those with HIV infection, organ transplant recipients, and patients with hematologic malignancies (2,3,5,6). However, because clinical cryptococcal isolates are not routinely subtyped to the serotype or species level, the actual incidence of C. gattii infection in HIV-negative persons is not known. In a US population-based surveillance study, 2 of 27 cryptococcal isolates obtained from HIV-negative persons were C. gattii (7). Although C. neoformans serotype A has been the most common cause of human disease worldwide since the HIV pandemic began, C. gattii may have previously caused proportionally more disease. For example, in Thailand in the pre-AIDS era, C. gattii comprised 66% of cryptococcal isolates, which decreased to ≈4% during the AIDS epidemic (8).
In general, cryptococcal disease can occur in 1 of 2 ways: a primary disease progression in the context of immunosuppression, or reactivation of a subclinical, latent infection. Progression from infection or colonization to disease likely depends upon a complex interplay of factors associated with the host and the organism.
The natural history of C. gattii infection is not well understood, but some studies suggest subtle differences in disease caused by C. gattii and C. neoformans. C. gattii causes cryptococcomas in the lung and brain (often large, multifocal lesions) more commonly than C. neoformans, and C. gattii disease is more often associated with neurologic sequelae, frequently requiring aggressive neurosurgical management (9,10). Differences in clinical manifestations and outcome suggested by some studies may in part be explained by differences in host immune status (9), although not all studies have demonstrated these differences (4).
Some reports have observed variable-to-decreased in vitro antifungal drug susceptibilities in clinical and environmental C. gattii isolates (11,12); other studies have shown no differences (4). Clinical significance of in vitro susceptibility of cryptococcal isolates is unclear because testing methods are not standardized and MIC breakpoints have not been defined.
C. gattii is found typically in the tropics and subtropics (2). Accordingly, although detected in many regions, C. gattii has been found to be endemic to Australia and New Zealand, Papua New Guinea, South and Southeast Asia (Cambodia, Malaysia, Thailand, Vietnam, People’s Republic of China, Taiwan, Singapore, Nepal, and the Indian subcontinent), parts of Latin America (Argentina, Brazil, Colombia, Uruguay, Paraguay, Peru, and Venezuela), southern California, Mexico, Hawaii, Central and South Africa, and certain parts of Europe (Austria, Germany, France, Italy, Greece, and Spain) (2,13).
Our understanding of the epidemiology of cryptococcosis is limited by our currently used diagnostic methods. Diagnosis of cryptococcosis frequently relies on direct microscopy, culture of clinical samples, or detection of cryptococcal antigen in body fluids. However, the organism is not identified to species level in many clinical microbiology laboratories. One biochemical characteristic that distinguishes C. gattii from C. neoformans is its ability to produce blue coloration on
Molecular typing studies, which are essential in tracking C. gattii epidemiology, have used the techniques of PCR fingerprinting (15), restriction fragment length polymorphism (RFLP) analysis (16), intergenic spacer sequencing (17), amplified fragment length polymorphism analysis (18), and more recently, multilocus sequence typing (MLST) (19,20). Molecular typing has identified distinct haploid C. gattii lineages among clinical, veterinary, and environmental isolates, such as VGI, VGII, VGIII, and VGIV (19,21,22), which appear to have distinct biogeoclimatic distribution zones. For example, most clinical isolates from Australia and eucalyptus-associated C. gattii isolates belong to molecular type VGI; VGII isolates have been found in domestic animals in Australia and in Aboriginal persons in the Northern Territory (2). On Vancouver Island and mainland British Columbia, most human, veterinary, and environmental C. gattii isolates belong to the genotype VGII, with its 2 molecular subtypes VGIIa (predominant genotype, ≈90% of VGII) and VGIIb (≈10%), representing 2 independent clonal populations (20,22,23).
Isolated cases of C. gattii disease were identified in the animal population of British Columbia in 2000 (24). C. gattii disease was recognized as an epidemic on Vancouver Island and lower mainland British Columbia (23,25) and retrospectively found to have been affecting residents and travelers to the island, as well as the domestic and wild animal population, since 1999 (24).
In 2003, cryptococcal infection became a reportable disease in British Columbia, which strengthened surveillance efforts. The British Columbia Centre for Disease Control reported a cumulative incidence of 218 C. gattii cases in humans during 1999–2007, with an average of 24.2 cases per year (26). The average annual incidence rate of C. gattii infection was 5.8 cases per million on mainland British Columbia and 25.1 cases per million on Vancouver Island; this rate is higher than those reported in other C. gattii–endemic areas of the world (27). During this same period, 19 deaths from C. gattii disease were documented, for a case-fatality rate of 8.7% (26). Of these 218 cases, 55% were in men; the mean age at diagnosis was 58.7 years. Possible risk factors included smoking, cancer, and HIV infection (26). Annual incidence, after reaching a plateau during 2000–2005, increased in 2006. Although most C. gattii cases have occurred among residents of Vancouver Island the numbers of cases have steadily increased among residents of lower mainland British Columbia, likely caused by an active expansion of the epidemic zone since 2004 from Vancouver Island to mainland British Columbia and the northwestern United States (Washington and Oregon) (27). The exact mode of transmission of C. gattii from Vancouver Island to lower mainland British Columbia is not known. However, studies of possible dispersal mechanisms have indicated an association of C. gattii cases with high-traffic locations, and evidence of anthropogenic dispersal through vehicle wheel wells, footwear, construction and forestry activity (leading to aerial dispersal), and water (23). A few domestic and international travelers to the disease-endemic zone on Vancouver Island have subsequently contracted cryptococcal disease caused by C. gattii VGIIa, the molecular subtype most commonly associated with the Vancouver Island emergence (28,29).
Use of MLST has documented that a C. gattii strain genetically similar to the Vancouver Island VGIIa strain caused disease in a patient in Seattle in 1971 (strain NIH444, also known as ATCC32609 and CBS6956). Another similar isolate was found in the environment in San Francisco, California, in 1990 (strain CBS7750) (20,22). These findings indicate that this subtype of C. gattii was present in the environment (and may have been a cause of human disease) in this part of the United States for many years before recognition of the Vancouver Island emergence (20). In recent years, several cases of C. gattii disease have been recognized in Washington and Oregon.
In early 2006, the first US case of human infection by a C. gattii strain identical to the Vancouver Island VGIIa (as confirmed by MLST) was diagnosed in a resident of Orcas Island, Washington (30). From 2006 through July 2008, a total of 9 additional culture-confirmed cases were reported in Washington in residents of Whatcom, Island, King, and San Juan counties (R. Baer, unpub. data). All C. gattii isolates from these patients in Washington belong to the VGIIa genotype, as indicated by RFLP (M. Morshed and L. Hoang, unpub. data) and MLST (31). Three of these 10 patients had no travel history to Vancouver Island or other C. gattii disease–endemic areas. In addition, 1 Washington resident with sarcoidosis received a diagnosis of C. gattii disease in Oregon; the isolate from this patient belonged to a novel VGII genotype, VGIIc (31). Washington State now considers C. gattii infection notifiable as a rare disease of public health significance (www.doh.wa.gov/notify/nc/cryptococcus.htm).
Cases of C. gattii disease have been identified in Oregon since 2004. During 2004–2005, two cases of culture-confirmed C. gattii infection were recorded in the United States. These case-patients did not report exposure to Vancouver Island or other C. gattii–endemic areas. Isolates from these case-patients (both Oregon residents) were VGII, but they were genetically distinct from Vancouver Island VGII isolates and their relationship to the outbreak is unknown (27). The current count is 19 confirmed cases, as of May 2009 (S. West and K.A. Marr, unpub. data). As with case-patients seen in British Columbia and Washington, many of these patients had pulmonary manifestations. A review of the travel history of these patients suggests in-state acquisition, although with the currently considered incubation period of 6 weeks to 11 months for C. gattii disease (27,28), out-of-state acquisition cannot be ruled out. Additional cases are suspected because of increased reports of cryptococcal disease documented in otherwise healthy persons (K.A. Marr, unpub. data). However, the current epidemiologic understanding of the extent and spread of C. gattii disease in Washington and Oregon is incomplete because of the lack of culture isolation and strain identification in clinical microbiology laboratories.
Cryptococcal disease in animals is often characterized by upper respiratory symptoms, subcutaneous nodules, pneumonia, central nervous system or ocular disorders, lymphadenopathy, or subcutaneous nodules (2,24,32). C. gattii infection was recognized in wild and domestic animals in British Columbia and Washington before human cases were detected, which reiterated the value of sentinel animal surveillance for emerging disease. To date, many species of animals, including dogs, cats, ferrets, porpoises, llamas, alpacas, birds, and a horse, have been confirmed to have C. gattii infections (23). During 2003–2005, C. gattii VGIIa infections were detected on the lower mainland of British Columbia (in 1 ferret, 1 llama, and 6 cats) (27) and in northern Washington (3 cats and 4 porpoises) (27; E. Byrnes, pers. comm.). From August 2006 through July 2008, C. gattii VGIIa was reported in 5 cats, 2 dogs, and 1 parrot in Whatcom, Island, Yakima, and Snohomish counties of Washington (R. Wohrle, pers. comm.). In Oregon, VGIIa C. gattii infection was found in 2007 in 1 cat in Lebanon, 1 dog in Salem, and 2 alpacas in McMinnville and Sherwood (33).
Identified risk factors for animals include disturbance of soil or vegetation caused by hiking, digging, logging, and construction. These activities can potentially increase aerial dispersal of the infectious particles and contact with soil and tree cuttings (23). The distribution of isolates recovered from human and animal sources and from the environment is shown in the Figure.
A possible association between C. gattii disease distribution and eucalyptus trees was observed in the early 1990s in Australia (2), and sporadically elsewhere (34,35). However, this association is not uniform (11), which indicates additional environmental sources. In British Columbia, C. gattii has been isolated from surfaces of >10 noneucalyptus tree species, soil, air, freshwater, and seawater within the Coastal Douglas Fir and Coastal Western Hemlock biogeoclimatic zones. These zones are characterized by warm, dry summers and mild, wet winters, a climate different from that traditionally associated with C. gattii (23). This finding suggests either a change in the ecology and distribution of this organism, or identification of a previously unrecognized niche (23,27).
From the beginning of the C. gattii epidemic on Vancouver Island and adjoining areas, all humans and animals with cryptococcal infection either lived within or traveled to the areas where C. gattii has been repeatedly and consistently isolated in subsequent studies (23,27). The Coastal Douglas Fir and Coastal Western Hemlock biogeoclimatic zones are located along the eastern edge of Vancouver Island, and extend into the southern Gulf Islands and lower mainland of British Columbia. Ecologic modeling of C. gattii in British Columbia has identified niche areas that are characterized by low-lying elevations (<770 m, average 100 m above sea level) and above freezing daily winter average temperatures (S. Mak, unpub. data). Similar climates with comparable temperature and rainfall extend further south into Washington and Oregon. Additionally, the San Juan Islands, Puget Sound, and the Willamette Valley contain plant diversity ecologically similar to that on Vancouver Island and in mainland British Columbia, lending support to the idea that C. gattii may have niche areas suitable for colonization in the broader Pacific Northwest (27).
Large-scale environmental sampling conducted from October 2001 through December 2005 in mainland British Columbia, the Gulf Islands, and Washington showed that 60 (3%) of 2,033 non-Vancouver Island environmental samples (air, water, soil, swabs of trees and other structures) were positive for C. gattii serotype B (58 VGIIa, 2 VGI) (27). C. gattii was consistently isolated from some areas. However, it was not found in the environment in other areas, such as the San Juan Islands (36), which suggests that environmental hot spots (zones of high concentration) of C. gattii may be found within the same broad ecologic niches. Some areas may have transient colonization, with initially positive sites yielding subsequent negative results (23).
Complicating the interpretation of epidemiologic data is the fact that the nature of the infectious propagule is currently unknown. Air sampling on Vancouver Island and in northern Washington has detected particles that are small enough to be either desiccated yeast cells or spores (23). Cryptococcus species are haploid yeasts that predominantly reproduce asexually (through mitosis and budding). However, they also possess a bipolar mating system, with mating types a or α. These mating types are capable of completing a sexual (meiotic) cycle that is either heterosexual (between a and α) or unisexual (nonclassical union between α and α or a and a; also known as monokaryotic fruiting) (21). This cycle can produce spores that can be up to 100-fold more infectious than yeast cells and thus might represent the infectious source (37). In tree hollows, C. gattii populations can exist equally as only α-mating type isolates or as a- and α-mating type isolates; both undergo recombination (38). This observation, taken together with the isolation of a diploid, homozygous α-mating type C. gattii strain from Vancouver Island, indicates that unique monokaryotic fruiting between α-mating type strains may be producing the infectious spores on Vancouver Island (20). Moreover, recent studies have shown that C. gattii is stimulated to complete its sexual cycle during an association with plants (39).
The origin or introduction of C. gattii strains into the Pacific Northwest and factors encouraging their emergence as disease agents remain a mystery. Accurate determination of origin from any particular locale is difficult because of global dispersal and isolate recombination (19). Several hypothesized disease movement models have been inconclusive. As discussed above, C. gattii VGIIa strains may have existed for the past 35 years in the Pacific Northwest, and changing conditions of climate, land use, or host susceptibility may have caused it to emerge at this time. An alternative hypothesis is that the VGIIa genotype is well adapted to the local biogeoclimatic conditions and enhanced with regards to virulence by virtue of the same-sex mating of the parents (20). Genetic studies putatively show that the dominant strain on Vancouver Island (VGIIa) originated in Australia, South America, or the Pacific Northwest. Conversely, the Vancouver Island minor genotype (VGIIb) is identical to fertile isolates from Australia and may well have originated on that continent (20,40).
We will now attempt to identify several major unmet needs regarding C. gattii disease in the areas of public health, human and veterinary medicine, environmental science, and microbiologic or basic research. Although enhancing a multidisciplinary awareness of C. gattii infection will encourage prompt, accurate diagnosis of patients with compatible clinical symptoms, many clinical microbiology laboratories in the United States are not currently equipped to identify the organism to the species level. Most laboratories use antigen testing or histopathologic analysis and report all isolates simply as C. neoformans; few laboratories use biochemical tests that provide species level differentiation. This practice should be reconsidered, especially in laboratories servicing disease-endemic regions.
Although formal C. gattii surveillance has been ongoing in British Columbia since 2003, no routine surveillance program currently exists in the United States. Therefore, identified cases almost certainly represent an underestimate of the actual incidence of disease. Washington State has recently initiated a surveillance system for human cryptococcosis cases (www.doh.wa.gov/notify/nc/cryptococcus.htm). However, to gather sufficient information about the true incidence of this disease and to perform necessary clinical studies, a coordinated, systematic, regional approach to human and veterinary surveillance is needed.
Currently, the University of British Columbia and the British Columbia Centre for Disease Control hold a large collection of C. gattii isolates isolated from environmental, animal, and human sources. Additional central repositories of C. gattii strains and clinical databases would be useful for investigators in the field.
Animal models of C gattii disease are necessary for studying the pathogenicity of genetically diverse isolates and host immunity, as well as to answer more fundamental questions about the disease. Laboratory-based efforts should also focus on development of better diagnostic aids, such as a reliable system to isolate DNA from fixed tissue. Development of species-specific serologic tests would enable seroprevalence studies for a better understanding of epidemiology and disease mechanisms. Studies of soil persistence and propagation of the organism and those that address the nature and factors controlling the infectious propagule would be informative (23).
Antifungal drug susceptibility testing represents an area in need of improvement. Current susceptibility testing methods do not consider the unique in vitro growth conditions of cryptococci, and interpretation of results is difficult in the absence of clinical breakpoints.
Some standardization in the performance of molecular techniques for genomic research is required. Different genotyping methods have their own particular advantages and disadvantages, and the method of choice varies considerably among different laboratories. Random amplified polymorphic DNA analysis, RFLP, and amplified fragment length polymorphism analysis provide a lower resolution starting point, but may not be sufficient to rigorously establish strain identities, for which MLST approaches are necessary. The appropriate method is obviously dependent on the desired level of discrimination of the strains. However, because the organism designations may vary with different methods, common nomenclature should be standardized across molecular methods. Finally, further genome efforts should be encouraged; information comparing the genetic makeup of VG (I–IV) lineages might hold the key to understanding the differences in niches, virulence, mating, and the ability to cause an outbreak.
From a long-term public health perspective, it is important to gain an understanding of how C. gattii disease was introduced and spread within the Pacific Northwest, including the possible role of global climate change, deforestation and increased land use, as well as factors related to the biology of the organism and changing host susceptibility. This knowledge, acquired through environmental and genomic research studies, would help identify high-risk groups or regions, and provide information on risk-reduction and improvement of diagnosis and treatment.
C. gattii has become endemic to the Pacific Northwest. Efforts to understand the emergence on Vancouver Island and mainland British Columbia have generated valuable information. However, many questions remain unanswered. The Centers for Disease Control and Prevention (Atlanta, GA, USA) is currently working in conjunction with state public health departments to enable clinical (human and veterinary) surveillance. Additional organized national and international efforts are needed. As the first step, C. gattii should be recognized as an emerging infection in the United States and declared a priority pathogen in the eyes of funding agencies.
Dr Datta is a postdoctoral fellow at Johns Hopkins University School of Medicine. His research interests include pathogenic fungi and evaluation of host immune responses to these pathogens.
- Kwon-Chung KJ, Varma A. Do major species concepts support one, two or more species within Cryptococcus neoformans? FEMS Yeast Res. 2006;6:574–87.
- Sorrell TC. Cryptococcus neoformans variety gattii. Med Mycol. 2001;39:155–68.
- Litvintseva AP, Thakur R, Reller LB, Mitchell TG. Prevalence of clinical isolates of Cryptococcus gattii serotype C among patients with AIDS in sub-Saharan Africa. J Infect Dis. 2005;192:888–92.
- Morgan J, McCarthy KM, Gould S, Fan K, Arthington-Skaggs B, Iqbal N, Cryptococcus gattii infection: characteristics and epidemiology of cases identified in a South African province with high HIV seroprevalence, 2002–2004. Clin Infect Dis. 2006;43:1077–80.
- Chaturvedi S, Dyavaiah M, Larsen RA, Chaturvedi V. Cryptococcus gattii in AIDS patients, southern California. Emerg Infect Dis. 2005;11:1686–92.
- Vilchez RA, Fung J, Kusne S. Cryptococcosis in organ transplant recipients: an overview. Am J Transplant. 2002;2:575–80.
- Brandt ME, Hutwagner LC, Klug LA, Baughman WS, Rimland D, Graviss EA, Molecular subtype distribution of Cryptococcus neoformans in four areas of the United States. Cryptococcal Disease Active Surveillance Group. J Clin Microbiol. 1996;34:912–7.
- Sukroongreung S, Nilakul C, Ruangsomboon O, Chuakul W, Eampokalap B. Serotypes of Cryptococcus neoformans isolated from patients prior to and during the AIDS era in Thailand. Mycopathologia. 1996;135:75–8.
- Chen S, Sorrell T, Nimmo G, Speed B, Currie B, Ellis D, Epidemiology and host- and variety-dependent characteristics of infection due to Cryptococcus neoformans in Australia and New Zealand. Australasian Cryptococcal Study Group. Clin Infect Dis. 2000;31:499–508.
- Grosse P, Tintelnot K, Sollner O, Schmitz B. Encephalomyelitis due to Cryptococcus neoformans var. gattii presenting as spinal tumour: case report and review of the literature. J Neurol Neurosurg Psychiatry. 2001;70:113–6.
- Khan ZU, Randhawa HS, Kowshik T, Chowdhary A, Chandy R. Antifungal susceptibility of Cryptococcus neoformans and Cryptococcus gattii isolates from decayed wood of trunk hollows of Ficus religiosa and Syzygium cumini trees in north-western India. J Antimicrob Chemother. 2007;60:312–6.
- Chen YC, Chang SC, Shih CC, Hung CC, Luhbd KT, Pan YS, Clinical features and in vitro susceptibilities of two varieties of Cryptococcus neoformans in Taiwan. Diagn Microbiol Infect Dis. 2000;36:175–83.
- Viviani MA, Cogliati M, Esposto MC, Lemmer K, Tintelnot K, Colom Valiente MF, Molecular analysis of 311 Cryptococcus neoformans isolates from a 30-month ECMM survey of cryptococcosis in Europe. FEMS Yeast Res. 2006;6:614–9.
- Kwon-Chung KJ, Polacheck I, Bennett JE. Improved diagnostic medium for separation of Cryptococcus neoformans var. neoformans (serotypes A and D) and Cryptococcus neoformans var. gattii (serotypes B and C). J Clin Microbiol. 1982;15:535–7.
- Ellis D, Marriott D, Hajjeh RA, Warnock D, Meyer W, Barton R. Epidemiology: surveillance of fungal infections. Med Mycol. 2000;38(Suppl 1):173–82.
- Meyer W, Castaneda A, Jackson S, Huynh M, Castaneda E. Molecular typing of IberoAmerican Cryptococcus neoformans isolates. Emerg Infect Dis. 2003;9:189–95.
- Diaz MR, Boekhout T, Kiesling T, Fell JW. Comparative analysis of the intergenic spacer regions and population structure of the species complex of the pathogenic yeast Cryptococcus neoformans. FEMS Yeast Res. 2005;5:1129–40.
- Boekhout T, Theelen B, Diaz M, Fell JW, Hop WC, Abeln EC, Hybrid genotypes in the pathogenic yeast Cryptococcus neoformans. Microbiology. 2001;147:891–907.
- Kidd SE, Guo H, Bartlett KH, Xu J, Kronstad JW. Comparative gene genealogies indicate that two clonal lineages of Cryptococcus gattii in British Columbia resemble strains from other geographical areas. Eukaryot Cell. 2005;4:1629–38.
- Fraser JA, Giles SS, Wenink EC, Geunes-Boyer SG, Wright JR, Diezmann S, Same-sex mating and the origin of the Vancouver Island Cryptococcus gattii outbreak. Nature. 2005;437:1360–4.
- Bovers M, Hagen F, Boekhout T. Diversity of the Cryptococcus neoformans–Cryptococcus gattii species complex. Rev Iberoam Micol. 2008;25:S4–12.
- Kidd SE, Hagen F, Tscharke RL, Huynh M, Bartlett KH, Fyfe M, A rare genotype of Cryptococcus gattii caused the cryptococcosis outbreak on Vancouver Island (British Columbia, Canada). Proc Natl Acad Sci U S A. 2004;101:17258–63.
- Bartlett KH, Kidd SE, Kronstad JW. The emergence of Cryptococcus gattii in British Columbia and the Pacific Northwest. Curr Infect Dis Rep. 2008;10:58–65.
- Stephen C, Lester S, Black W, Fyfe M, Raverty S. Multispecies outbreak of cryptococcosis on southern Vancouver Island, British Columbia. Can Vet J. 2002;43:792–4.
- Fyfe M, MacDougall L, Romney M, Starr M, Pearce M, Mak S, Cryptococcus gattii infections on Vancouver Island, British Columbia, Canada: emergence of a tropical fungus in a temperate environment. Can Commun Dis Rep. 2008;34:1–12.
- Galanis E, MacDougall L, Li M, Woolcott J, Mitchell R, Peng Y, Burden of illness and risk factors for C. gattii infection in British Columbia (BC), Canada, 1999–2007. Presented at: 7th International Conference on Cryptococcus and Cryptococcosis; 2008 Sep 11–14; Nagasaki, Japan. Poster A-24.
- MacDougall L, Kidd SE, Galanis E, Mak S, Leslie MJ, Cieslak PR, Spread of Cryptococcus gattii in British Columbia, Canada, and detection in the Pacific Northwest, USA. Emerg Infect Dis. 2007;13:42–50.
- Lindberg J, Hagen F, Laursen A, Stenderup J, Boekhout T. Cryptococcus gattii risk for tourists visiting Vancouver Island, Canada. Emerg Infect Dis. 2007;13:178–9.
- Levy R, Pitout J, Long P, Gill MJ. Late presentation of Cryptococcus gattii meningitis in a traveller to Vancouver Island: a case report. Can J Infect Dis Med Microbiol. 2007;18:197–9.
- Upton A, Fraser JA, Kidd SE, Bretz C, Bartlett KH, Heitman J, First contemporary case of human infection with Cryptococcus gattii in Puget Sound: evidence for spread of the Vancouver Island outbreak. J Clin Microbiol. 2007;45:3086–8.
- Byrnes EJ III, Bildfell R, Frank SA, Mitchell TG, Marr K, Heitman J. Molecular evidence that the Vancouver Island Cryptococcus gattii outbreak has expanded into the United States Pacific Northwest. J Infect Dis. 2009;199:1081–6.
- Duncan C, Stephen C, Lester S, Bartlett KH. Follow-up study of dogs and cats with asymptomatic Cryptococcus gattii infection or nasal colonization. Med Mycol. 2005;43:663–6.
- Byrnes EJ III, Bildfell RJ, Dearing PL, Valentine BA, Heitman J. Cryptococcus gattii with bimorphic colony types in a dog in western Oregon: additional evidence for expansion of the Vancouver Island outbreak. J Vet Diagn Invest. 2009;21:133–6.
- Campisi E, Mancianti F, Pini G, Faggi E, Gargani G. Investigation in central Italy of the possible association between Cryptococcus neoformans var. gattii and Eucalyptus camaldulensis. Eur J Epidemiol. 2003;18:357–62.
- Gugnani HC, Mitchell TG, Litvintseva AP, Lengeler KB, Heitman J, Kumar A, Isolation of Cryptococcus gattii and Cryptococcus neoformans var. grubii from the flowers and bark of eucalyptus trees in India. Med Mycol. 2005;43:565–9.
- Fraser JA, Lim SM, Diezmann S, Wenink EC, Arndt CG, Cox GM, Yeast diversity sampling on the San Juan Islands reveals no evidence for the spread of the Vancouver Island Cryptococcus gattii outbreak to this locale. FEMS Yeast Res. 2006;6:620–4.
- Sukroongreung S, Kitiniyom K, Nilakul C, Tantimavanich S. Pathogenicity of basidiospores of Filobasidiella neoformans var. neoformans. Med Mycol. 1998;36:419–24.
- Saul N, Krockenberger M, Carter D. Evidence of recombination in mixed-mating-type and alpha-only populations of Cryptococcus gattii sourced from single eucalyptus tree hollows. Eukaryot Cell. 2008;7:727–34.
- Xue C, Tada Y, Dong X, Heitman J. The human fungal pathogen Cryptococcus can complete its sexual cycle during a pathogenic association with plants. Cell Host Microbe. 2007;1:263–73.
- Campbell LT, Currie BJ, Krockenberger M, Malik R, Meyer W, Heitman J, Clonality and recombination in genetically differentiated subgroups of Cryptococcus gattii. Eukaryot Cell. 2005;4:1403–9.
- Figure. Map of the Pacific Northwest, comprising parts of British Columbia, Canada, and the states of Washington and Oregon in the United States, showing human and veterinary Cryptococcus gattii cases (including...
Suggested citation for this article: Datta K, Bartlett KH, Baer R, Byrnes E, Galanis E, Heitman J, et al. Spread of Cryptococcus gattii into Pacific Northwest region of the United States. Emerg Infect Dis [serial on the Internet]. 2009 Aug [date cited]. Available from http://wwwnc.cdc.gov/eid/article/15/8/08-1384
1The Cryptococcus gattii Working Group of the Pacific Northwest includes the authors of this report and the following members: Jim Kronstad and Theodore Steiner, University of British Columbia, Vancouver, British Columbia, Canada; Sarah West, Oregon Health and Science University, Portland, OR, USA; Emilio DeBess, Oregon State Department of Human Services, Salem, OR, USA; Tom Chiller, Centers for Disease Control and Prevention, Atlanta, GA, USA; Craig Stephen, University of Calgary, Calgary, Alberta, Canada; Ron Wohrle, Washington State Department of Health, Olympia, WA, USA; Peter Phillips, St. Paul’s Hospital, University of British Columbia; Thomas G. Mitchell, Duke University, Durham, NC, USA; Robert Bildfell, Beth Valentine, and Peggy Dearing, Oregon State University, Corvallis, OR, USA; Rob Barnes, Peace Health Medical Group, Eugene, OR, USA; Ajit Limaye, University of Washington, Seattle, WA, USA; Richard Ferguson, Claire Beiser, and Sara Mostad, St. Joseph Hospital, Bellingham, WA, USA; Sarah Kidd, Monash University, Melbourne, Victoria, Australia; Greg Stern, Whatcom County Health Department, Bellingham; and Sunny Mak, British Columbia Centre for Disease Control, Vancouver, British Columbia, Canada.
Please use the form below to submit correspondence to the authors or contact them at the following address:
Kieren A. Marr, Division of Infectious Diseases, Johns Hopkins University School of Medicine, 720 Rutland Ave, Ross Research Bldg, Rm 1064, Baltimore, MD 21205, USA
Comment submitted successfully, thank you for your feedback.
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
- Page created: November 03, 2010
- Page last updated: November 03, 2010
- Page last reviewed: November 03, 2010
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)